Cramer on how investors should handle stay-at-home stock slump on Pfizer vaccine news

Dow futures surged on the news that data from the coronavirus vaccine trial out of Pfizer and German biotech firm BioNTech shows the vaccine is more than 90% effective in preventing Covid-19 among those without evidence of prior infection. CNBC's Jim Cramer, Carl Quintanilla and David Faber discuss what this means for technology stocks that have risen during the pandemic.
Mon, Nov 9 202010:25 AM EST